Belfast investor presentation

RNS Number : 0981D

Fusion Antibodies PLC

17 February 2020

 

Fusion Antibodies plc

("Fusion" or the "Company")

Belfast investor presentation

Fusion Antibodies plc (AIM: FAB), specialists in pre-clinical antibody discovery, engineering and supply for both therapeutic drug and diagnostic applications, announces that it will hold a presentation for investors on Monday, 6 April 2020 in Belfast City. The event will be held jointly by Fusion and Diaceutics PLC, the diagnostic commercialisation company.

On behalf of Fusion, Dr Paul Kerr, CEO and James Fair, CFO, will give a Company update and overview. Richard Buick, CTO, will also be in attendance. The event will take place at a venue in central Belfast and will commence with registration at 5.00pm for a 5.15pm start, followed by drinks and networking.

No new price sensitive information will be disclosed at the presentation.

5pm: arrival and registration

5.15pm: Welcome address

5.20pm - 5.50pm: Diaceutics presentation

5.50pm - 6.05pm: Q&A

6.10pm - 6.40pm: Fusion Antibodies presentation

6.40pm - 6.55pm: Q&A

7pm: Canapes, drinks and networking

8pm: Close

If you would like to register to attend, please contact Walbrook PR on 020 7933 8780 or email [e-mail]. 

Enquiries:

Fusion Antibodies plc		www.fusionantibodies.com
Dr Paul Kerr, Chief Executive Officer		Via Walbrook PR
James Fair, Chief Financial Officer
Walbrook PR	Tel: [phone] or [e-mail]
Anna Dunphy	Mob: [phone]
Paul McManus	Mob: [phone]

About Fusion Antibodies plc

Fusion is a Belfast based contract research organisation ("CRO") providing a range of antibody engineering services for the development of antibodies for both therapeutic drug and diagnostic applications.

The Company's ordinary shares were admitted to trading on AIM on 18 December 2017. Fusion provides a broad range of services in antibody generation, development, production, characterisation and optimisation. These services include antigen expression, antibody production, purification and sequencing, antibody humanisation using Fusion's proprietary CDRx^TM platform and the production of antibody generating stable cell lines to provide material for use in clinical trials. Since 2012, the Company has successfully sequenced and expressed over 250 antibodies and successfully completed over 150 humanisation projects for its international, blue-chip client base, which has included eight of the top 10 global pharmaceutical companies by revenue.

The Company was established in 2001 as a spin out from Queen's University Belfast. The Company's mission is to enable pharmaceutical and diagnostic companies to develop innovative products in a timely and cost-effective manner for the benefit of the global healthcare industry. Fusion Antibodies provides a broad range of services in antibody generation, development, production, characterisation and optimisation.

Fusion Antibodies growth strategy is based on combining the latest technological advances with cutting edge science to deliver new platforms that will enable Pharma and Biotechs get to the clinic faster, with the optimal drug candidate and ultimately speed up the drug development process. 

The global monoclonal antibody therapeutics market was valued at $95.5 billion in 2017 and is forecast to surpass $174.2 billion in 2026, an increase at a CAGR of between 6.9 per cent. for the period 2018 to 2026. In 2018, seven of the world's ten top selling drugs were antibody-based therapeutics with the combined annual sales of these drugs exceeding $62 billion.  

 

END

 

 

NRABXGDDDDBDGGS